Monoacylglycerol lipase modulators

Abstract

3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R 1 , R 2a , and R 2b are defined herein.

1 - 28 . (canceled) 
     
     
         29 . A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound of Formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         X is CH 2  or O; 
         Y is selected from the group consisting of: 
       
       
         
           
           
               
               
           
         
         R 1  is H; 
         R 2a  and R 2b  are each independently H; 
         R 3  is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C 1-6 alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C 1-6 alkyl, C 1-6 alkyl substituted with OH, C 1-6 alkyl substituted with CO 2 H, C 1-6 haloalkyl, OC 1-6 haloalkyl, C 3-6 cycloalkyl, O-phenyl, and C 3-6 cycloalkyl substituted with CH 3 ; 
         R a  and R b  are each independently selected from the group consisting of: H and halo; and 
         R c  is H or CH 3 ; 
         and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of compounds of Formula (I). 
       
     
     
         30 . The method of  claim 29 , wherein the MGL receptor mediated disease, disorder, or condition is selected from the group consisting of: pain, psychiatric conditions, neurological conditions, cancers, and eye conditions. 
     
     
         31 . The method of  claim 30 , wherein the MGL receptor mediated disease, disorder or condition is selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression, and bipolar disorder. 
     
     
         32 . The method of  claim 30 , wherein the MGL receptor mediated disease, disorder or condition is inflammatory pain.